Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life.

Burden of disease Conceptual model HCM symptoms Hypertrophic cardiomyopathy Patient-reported outcomes Quality of life Shortness of breath

Journal

Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688

Informations de publication

Date de publication:
01 Dec 2020
Historique:
received: 28 07 2020
accepted: 18 11 2020
entrez: 1 12 2020
pubmed: 2 12 2020
medline: 2 12 2020
Statut: epublish

Résumé

Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder defined by left ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. There is a general lack of knowledge about patients' perspectives on the symptoms and day-to-day limitations they experience as a result of HCM. We therefore sought an in-depth understanding of patients' experiences of obstructive (oHCM) and nonobstructive (nHCM) forms of the disease, including symptoms and their quality of life impacts, and to develop a conceptual model to capture them. Development of the HCM conceptual model involved a web-based survey to capture patients' insights, a targeted literature review (which included relevant guidelines and patient advocacy websites), one-to-one interviews with clinical experts, and one-to-one qualitative concept elicitation interviews with patients. Key symptoms and their impacts most important to patients' experiences were identified and used to develop a conceptual model of the patient experience with HCM. The HCM symptoms reported by patient interviewees (n = 27) were largely consistent with findings from the patient web survey (n = 444), literature review, and interviews with three expert clinicians. The symptoms most commonly reported in patient interviews included tiredness (89%), shortness of breath (89%), shortness of breath with physical activity (89%), and dizziness/light-headedness (89%). Other symptoms commonly reported included chest pain (angina) (70%), chest pain (angina) with physical exertion (70%), and palpitations (fluttering or rapid heartbeat) (81%). The most commonly reported impacts of HCM symptoms on patients' lives included limitations to physical activities (78%), emotional impacts, including feeling anxious or depressed (78%), and impacts on work (63%). Symptoms and impacts were similar for both oHCM and nHCM. A conceptual model was developed, which identifies the core symptoms that patients with oHCM and nHCM reported as most frequent and most important: shortness of breath, palpitations, fatigue/tiredness, dizziness/light-headedness, and chest pain, as well as the impacts those symptoms have on patients' lives. This HCM conceptual model reflecting patients' experiences and perspectives was used in the development of a patient-reported outcomes instrument for use in clinical trials and it may also help inform the clinical management of HCM.

Sections du résumé

BACKGROUND BACKGROUND
Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder defined by left ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. There is a general lack of knowledge about patients' perspectives on the symptoms and day-to-day limitations they experience as a result of HCM. We therefore sought an in-depth understanding of patients' experiences of obstructive (oHCM) and nonobstructive (nHCM) forms of the disease, including symptoms and their quality of life impacts, and to develop a conceptual model to capture them.
METHODS METHODS
Development of the HCM conceptual model involved a web-based survey to capture patients' insights, a targeted literature review (which included relevant guidelines and patient advocacy websites), one-to-one interviews with clinical experts, and one-to-one qualitative concept elicitation interviews with patients. Key symptoms and their impacts most important to patients' experiences were identified and used to develop a conceptual model of the patient experience with HCM.
RESULTS RESULTS
The HCM symptoms reported by patient interviewees (n = 27) were largely consistent with findings from the patient web survey (n = 444), literature review, and interviews with three expert clinicians. The symptoms most commonly reported in patient interviews included tiredness (89%), shortness of breath (89%), shortness of breath with physical activity (89%), and dizziness/light-headedness (89%). Other symptoms commonly reported included chest pain (angina) (70%), chest pain (angina) with physical exertion (70%), and palpitations (fluttering or rapid heartbeat) (81%). The most commonly reported impacts of HCM symptoms on patients' lives included limitations to physical activities (78%), emotional impacts, including feeling anxious or depressed (78%), and impacts on work (63%). Symptoms and impacts were similar for both oHCM and nHCM.
CONCLUSIONS CONCLUSIONS
A conceptual model was developed, which identifies the core symptoms that patients with oHCM and nHCM reported as most frequent and most important: shortness of breath, palpitations, fatigue/tiredness, dizziness/light-headedness, and chest pain, as well as the impacts those symptoms have on patients' lives. This HCM conceptual model reflecting patients' experiences and perspectives was used in the development of a patient-reported outcomes instrument for use in clinical trials and it may also help inform the clinical management of HCM.

Identifiants

pubmed: 33259041
doi: 10.1186/s41687-020-00269-8
pii: 10.1186/s41687-020-00269-8
pmc: PMC7708573
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102

Références

Circulation. 2011 Dec 13;124(24):2761-96
pubmed: 22068435
J Am Heart Assoc. 2018 Feb 25;7(5):
pubmed: 29478967
Genet Med. 2010 Nov;12(11):655-67
pubmed: 20864896
Am Heart J. 2015 Jul;170(1):87-95, 95.e1-4
pubmed: 26093868
Circ Heart Fail. 2015 Nov;8(6):1022-31
pubmed: 26374874
Am Heart J. 2015 May;169(5):684-692.e1
pubmed: 25965716
Am J Med. 2016 May;129(5):486-496.e2
pubmed: 26800575
Heart. 1997 Aug;78(2):182-7
pubmed: 9326995
Am J Med Genet A. 2009 Feb 15;149A(4):602-12
pubmed: 19253387
Am J Cardiol. 2000 Jul 15;86(2):162-8
pubmed: 10913477
Catheter Cardiovasc Interv. 2016 Nov 15;88(6):953-960
pubmed: 27143093
Am J Cardiol. 2012 May 15;109(10):1494-8
pubmed: 22356797
J Am Coll Cardiol. 1993 Jun;21(7):1672-9
pubmed: 8496536
Open Heart. 2016 Oct 17;3(2):e000488
pubmed: 27843566
Am J Cardiol. 2016 Mar 15;117(6):961-5
pubmed: 26810858
Circulation. 2015 Jul 7;132(1):10-9
pubmed: 25977310
JACC Heart Fail. 2015 May;3(5):408-418
pubmed: 25863972
Am J Cardiol. 2013 Oct 15;112(8):1182-9
pubmed: 24079444
Circulation. 2009 Mar 3;119(8):1085-92
pubmed: 19221222
Int J Cardiol. 2015 Apr 1;184:743-9
pubmed: 25827935
Heart Lung Circ. 2011 Nov;20(11):688-90
pubmed: 22000299
Am J Cardiol. 2013 Apr 1;111(7):1034-9
pubmed: 23340032
Circulation. 2018 Oct 2;138(14):1387-1398
pubmed: 30297972
Health Qual Life Outcomes. 2016 Apr 14;14:62
pubmed: 27079917
JAMA. 2017 Apr 4;317(13):1349-1357
pubmed: 28306757
Eur Heart J. 2014 Oct 14;35(39):2733-79
pubmed: 25173338
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
J Am Coll Cardiol. 2013 Jul 30;62(5):449-57
pubmed: 23643593
N Engl J Med. 2003 Jan 23;348(4):295-303
pubmed: 12540642
Open Heart. 2016 Jul 20;3(2):e000484
pubmed: 27547438
N Engl J Med. 2016 Jun 23;374(25):2441-52
pubmed: 27332903
Circulation. 2016 Jan 5;133(1):62-73
pubmed: 26518766
Circulation. 2003 Oct 28;108(17):e118-21
pubmed: 14581388

Auteurs

Erica Zaiser (E)

Evidera, London, UK.

Amy J Sehnert (AJ)

MyoKardia, Inc, Brisbane, California, USA.

Ashley Duenas (A)

Evidera, London, UK.

Sara Saberi (S)

Frankel Cardiovascular Center, University of Michigan Hospital, Michigan Medicine, Ann Arbor, Michigan, USA.

Ella Brookes (E)

Evidera, London, UK.

Matthew Reaney (M)

IQVIA, 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, UK. matthew.reaney@iqvia.com.

Classifications MeSH